openPR Logo
Press release

Monoclonal Antibodies in Veterinary Health Market to Reach USD 2.5 Bn by 2034

09-25-2025 02:20 PM CET | Health & Medicine

Press release from: Exactitude Consultancy

Monoclonal Antibodies in Veterinary Health Market

Monoclonal Antibodies in Veterinary Health Market

Introduction
The adoption of monoclonal antibodies (mAbs) in veterinary health represents a groundbreaking advancement in animal medicine. Once primarily associated with human healthcare, mAbs are now being developed for companion and livestock animals to treat conditions such as cancer, infections, and chronic inflammatory diseases. Their ability to target specific antigens with precision makes them one of the most promising therapeutic modalities for animal health.

As pet ownership rises globally and demand for advanced veterinary therapeutics grows, the market for monoclonal antibodies in veterinary health is gaining traction. By 2024, the market size is estimated at USD 0.7 billion and is projected to reach USD 2.5 billion by 2034, expanding at a CAGR of 13.5% during 2025-2034.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72402

Market Overview
Key highlights of the global monoclonal antibodies in veterinary health market:
• Market Size 2024: USD 0.7 billion
• Forecast 2034: USD 2.5 billion
• CAGR (2025-2034): ~13.5%
• Key Drivers: Rising pet ownership, increasing prevalence of chronic animal diseases, demand for precision therapeutics in veterinary medicine, and growing awareness of pet health.
• Challenges: High development and production costs, limited approvals compared to human biologics, and regulatory complexities.
• Leading Players: Zoetis, Elanco Animal Health, Merck Animal Health, Boehringer Ingelheim, Virbac, Ceva Santé Animale, IDEXX Laboratories, Regeneron (in collaborations), Aratana Therapeutics, and Kindred Biosciences.

The market is innovation-driven, with companies focusing on developing targeted therapies for canine osteoarthritis, feline infectious diseases, and cancer in pets.

Segmentation Analysis
By Product Type
• Therapeutic Monoclonal Antibodies
• Diagnostic Monoclonal Antibodies

By Animal Type
• Companion Animals
o Dogs
o Cats
o Horses
• Livestock Animals
o Cattle
o Poultry
o Swine

By Application
• Cancer
• Infectious Diseases
• Inflammatory & Autoimmune Diseases
• Pain Management
• Others

By Distribution Channel
• Veterinary Hospitals & Clinics
• Retail Pharmacies
• Online Pharmacies

Summary:
Companion animals, particularly dogs, represent the largest consumer base for veterinary mAbs, with applications in chronic pain and cancer therapy. Diagnostic mAbs are also gaining adoption for rapid disease detection in both pets and livestock.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72402/monoclonal-antibodies-in-veterinary-health-market

Regional Analysis
North America
• Largest market share, driven by high pet ownership, advanced veterinary healthcare infrastructure, and early approvals of veterinary monoclonal antibodies.
• The U.S. leads with companies like Zoetis and Elanco driving innovation.
Europe
• Strong growth in Germany, France, and the UK, supported by stringent animal health regulations and rising demand for advanced therapies.
• Expansion of pet insurance coverage boosts affordability of treatments.
Asia-Pacific
• Expected to post the fastest CAGR through 2034, supported by growing middle-class pet ownership, rising veterinary awareness, and expanding animal healthcare investments in China, Japan, India, and South Korea.
Middle East & Africa
• Gradual adoption, primarily in urban and developed veterinary settings across the GCC.
• Limited infrastructure and high costs remain barriers in Africa.
Latin America
• Brazil and Mexico lead, with growing adoption of veterinary biologics for both companion and livestock animals.

Summary:
While North America and Europe dominate, Asia-Pacific is emerging as the fastest-growing region, thanks to expanding pet care markets and livestock disease management programs.

Market Dynamics
Key Growth Drivers
• Rising prevalence of chronic diseases in pets such as osteoarthritis and cancer.
• Increasing humanization of pets and willingness of owners to invest in advanced care.
• Technological advancements in veterinary biologics and precision medicine.
• Expanding pet insurance coverage in developed markets.
• Growing applications of diagnostic mAbs in animal disease detection.

Key Challenges
• High production and R&D costs limiting accessibility.
• Regulatory hurdles and fewer product approvals compared to human biologics.
• Limited awareness and adoption in developing countries.
• Cold chain and distribution challenges in low-infrastructure markets.

Latest Trends
• Development of canine-specific monoclonal antibodies for arthritis and allergies.
• Expansion of mAb-based diagnostics for rapid livestock disease detection.
• Increasing collaborations between human biotech firms and veterinary companies.
• Growing use of biosimilars to make treatments more affordable.
• Integration of mAbs in theranostics, combining diagnostics with therapy.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72402

Competitor Analysis
Major Players
• Zoetis - Leader with mAb therapies for canine osteoarthritis (e.g., Librela).
• Elanco Animal Health - Strong pipeline in companion animal therapeutics.
• Merck Animal Health - Expanding veterinary biologics portfolio.
• Boehringer Ingelheim - Focused on immunotherapies and biologics for pets.
• Virbac - Diversified animal health products, entering biologics space.
• Ceva Santé Animale - Developing targeted veterinary therapeutics.
• IDEXX Laboratories - Expanding diagnostic mAbs for companion and livestock animals.
• Regeneron & Aratana Therapeutics - Collaborating on novel veterinary mAb therapies.
• Kindred Biosciences - Focused exclusively on biologics for veterinary use.

Summary:
Competition is centered around innovation, clinical validation, and regulatory approvals. Zoetis currently dominates with commercialized veterinary mAbs, while Elanco and Boehringer Ingelheim are strengthening their pipelines.

Conclusion
The monoclonal antibodies in veterinary health market is set to grow significantly, increasing from USD 0.7 billion in 2024 to USD 2.5 billion by 2034, at a CAGR of 13.5%.

Key Takeaways:
• Companion animals, especially dogs, are the largest market segment.
• Therapeutic mAbs dominate, with diagnostic mAbs gaining traction.
• North America leads today, but Asia-Pacific is the fastest-growing region.
• Innovation, affordability, and regulatory clarity will shape future growth.

This report is also available in the following languages : Japanese (獣医医薬品市場におけるモノクローナル抗体), Korean (수의학 건강 시장의 단일클론 항체), Chinese (兽医保健市场中的单克隆抗体), French (Anticorps monoclonaux sur le marché de la santé vétérinaire), German (Monoklonale Antikörper im Veterinärgesundheitsmarkt), and Italian (Anticorpi monoclonali nel mercato della salute veterinaria), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72402

Our More Reports:

Next Generation Drug Conjugates Market
https://exactitudeconsultancy.com/reports/72418/next-generation-drug-conjugates-market

Plasmid DNA Manufacturing Market
https://exactitudeconsultancy.com/reports/72420/plasmid-dna-manufacturing-market

Nanoparticle Formulation Market
https://exactitudeconsultancy.com/reports/72422/nanoparticle-formulation-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Monoclonal Antibodies in Veterinary Health Market to Reach USD 2.5 Bn by 2034 here

News-ID: 4198275 • Views:

More Releases from Exactitude Consultancy

Sterile Injectable Contract Manufacturing Market to Reach USD 72.6 Bn by 2034 at 8.7% CAGR
Sterile Injectable Contract Manufacturing Market to Reach USD 72.6 Bn by 2034 at …
Introduction The global demand for sterile injectable drugs has surged, driven by the increasing prevalence of chronic and infectious diseases, the rise of biologics, and the growing emphasis on targeted therapies. As pharmaceutical companies face pressure to accelerate time-to-market and manage costs, contract manufacturing organizations (CMOs) have emerged as crucial partners in sterile injectable production. Sterile injectable contract manufacturing ensures compliance with stringent regulatory requirements, advanced aseptic processing, and scalability for both
Hair Transplant Market Set to Surge, Reaching USD 25.9 Billion by 2034 at 13.6% CAGR
Hair Transplant Market Set to Surge, Reaching USD 25.9 Billion by 2034 at 13.6% …
Introduction Hair loss, or alopecia, affects millions of people globally and has significant psychological and social implications. While topical treatments and oral medications remain common, hair transplant procedures have emerged as the most effective long-term solution for restoring natural hair growth. Technological advancements such as robotic-assisted surgery, minimally invasive techniques, and platelet-rich plasma (PRP) therapy have made hair restoration more accessible and effective. By 2024, the hair transplant market size is estimated
BRIC Non-Vascular Stents Market Forecasted to Reach USD 1.4 Billion by 2034
BRIC Non-Vascular Stents Market Forecasted to Reach USD 1.4 Billion by 2034
The global healthcare industry is evolving rapidly, with innovative medical devices transforming patient outcomes and redefining standards of care. One such device gaining remarkable traction is the non-vascular stent-an implantable medical device used to maintain the patency of non-vascular luminal structures such as the biliary duct, esophagus, trachea, colon, and urinary tract. In the BRIC region (Brazil, Russia, India, China), the non-vascular stents market is experiencing accelerated growth, driven by
Nutraceutical Product Testing Market Poised to Grow at 8.2% CAGR, Reaching USD 14.2 Billion by 2034
Nutraceutical Product Testing Market Poised to Grow at 8.2% CAGR, Reaching USD 1 …
Introduction The global nutraceutical industry is experiencing exponential growth, fueled by rising consumer demand for supplements, functional foods, and fortified beverages. However, as demand grows, so does the need for nutraceutical product testing, which ensures safety, efficacy, and compliance with stringent regulatory standards across global markets. Nutraceutical testing includes quality assurance for raw materials, microbial and chemical contaminant analysis, label claim verification, and bioactive compound quantification. With increasing consumer expectations and tighter

All 5 Releases


More Releases for Animal

Animal Health Market Sets the Table for Continued Growth : Zoetis Animal Healthc …
Advance Market Analytics published a new research publication on "Animal Health Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Animal Health market was mainly driven by the increasing R&D spending across the world. Some of the key players profiled
Animal Antimicrobials and Antibiotics Market 2023 Growth and Development By Bion …
Antibiotics, also called antibacterials, are a type of antimicrobial drug used in the treatment and prevention of bacterial infections. They may either kill or inhibit the growth of bacteria. Animal Antimicrobials and Antibiotics includes Premixes, Oral Powders, Oral Solutions and Injections on the base of classification, which represent 12.4%, 14.4%, 10.4% and 56.6% of global Animal Antimicrobials and Antibiotics market. Get Sample Copy: https://www.worldwidemarketreports.com/sample/273708 Farm Animals and Companion Animals are the
Animal Healthcare Market Analysis Focusing on Top Key Players - Merck, Bayer Ani …
Worldwide Market Reports recently released on the Animal Healthcare market for the forecast period, 2017 – 2022 is involved in screening the business environment and the companies operating in the Animal Healthcare industry. Importantly, the research sheds a lot of light on their winning strategies to help stakeholders, business owners, and field marketing executives stay ahead in the competition. Besides, the industry is thoroughly weighed upon on the basis of
Animal Model Market trends, Animal Model Market growth, Animal Model Market size …
Key Findings of Animal Model Market Developing Regions to Overpower Developed Ones With Regard to Demand The Asian territory is on the verge of evolving as the next big destination for animal models. This growth can be attributed to various factors such as American and European pharmaceutical companies diversifying their research activities to curtail extra expenses and save costs. Although U.S and Europe have retained their legacy in the global market, their
Animal Growth Promoter Market Outlook To 2023 – Bayer Animal Health, Biomin, B …
Nov 2018, New York USA (News)- Different categories of feed additives for farm animals are referred to as natural growth promoters (NGPs) or non-antibiotic growth promoters. They are commonly regarded as favorable alternatives to antibiotic growth promoters (AGPs) in livestock production. NGPs include predominantly organic acids, probiotics, prebiotics, synbiotics, phytogenics, tannins, feed enzymes and immune stimulants, an ongoing search for alternatives has created a large variety of NGPs for pigs,
Animal Antimicrobials and Antibiotics Market Key Players : Animal Health, Bayer …
The term antibiotic or antimicrobial is used for those agents who kill or inhibit the growth of microorganism. The antimicrobials products have significant benefits to the animal and to human food safety. There are researches, which have proven that an increase in the rate of animal illness results in higher rate of human illness. Therefore, livestock dealers depend on animal antibiotics to provide safe food. The scope of this report